{"filing":{"accession_number":"0001193125-26-343473","cik":"0001835022","ticker":"COYA","company_name":"Coya Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"coya-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/coya-20260811.htm"},"events":[{"id":26903,"run_id":24470,"accession_number":"0001193125-26-343473","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 11, 2026 disclosing financial results for the quarter ended June 30, 2026, including collaboration revenue, R\u0026D and G\u0026A expenses, net loss of $6.6 million, and cash position of $43.2 million. The filing includes condensed balance sheets, statements of operations, and cash flow statements for the interim period, along with corporate highlights and forward-looking guidance on clinical trial milestones. This is material to investors assessing the company's financial condition and operational progress.","company_name":"Coya Therapeutics, Inc.","ticker":"COYA","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28197,"accession_number":"0001193125-26-343473","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 11, 2026 disclosing financial results for the quarter ended June 30, 2026, including collaboration revenue, R\u0026D and G\u0026A expenses, net loss of $6.6 million, and cash position of $43.2 million. The filing includes condensed balance sheets, statements of operations, and cash flow statements for the interim period, along with corporate highlights and forward-looking guidance on clinical trial milestones. This is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:04:37.635421+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28197,"accession_number":"0001193125-26-343473","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 11, 2026 disclosing financial results for the quarter ended June 30, 2026, including collaboration revenue, R\u0026D and G\u0026A expenses, net loss of $6.6 million, and cash position of $43.2 million. The filing includes condensed balance sheets, statements of operations, and cash flow statements for the interim period, along with corporate highlights and forward-looking guidance on clinical trial milestones. This is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:04:37.635421+00:00","company_name":"Coya Therapeutics, Inc.","ticker":"COYA","filing_date":"2026-08-11"}]}